Allen J Dozor MD Appointed President of Boston Children’s Health Physicians

Allen J Dozor MD  has a long and distinguished history with the organization, most recently serving as Interim Vice President since April 2020.

Dr. Dozor is a longtime member of the Boston Children’s family since he joined the faculty and attending staff at Boston Children’s Hospital in 1982. Dr. Dozor moved to Westchester and accepted the position of Chief of Pediatric Pulmonology at New York Medical College and Director of the Pediatric Intensive Care Unit at Westchester Medical Center in 1985 and has since devoted his professional career to the growth of the organization, to the care of patients, and to the advancement of multiple academic endeavors.

Allen J Dozor MD founded the Division of Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine at BCHP (formerly CWPW) and has also served as the Director of the Armond V. Mascia, MD Cystic Fibrosis Center, the only such center in the Hudson Valley. Additionally, he founded and directed the fellowship in Pediatric Pulmonology, he has served as the Associate Physician-in-Chief at Maria Fareri Children’s Hospital at Westchester Medical Center since its inception, and in 2008 he co-founded the Children’s Environmental Health Center of the Hudson Valley. Dr. Dozor also serves as Professor of Pediatrics and Clinical Public Health at New York Medical College.

“We are grateful for the many contributions which Dr. Dozor has made to the field of Pediatrics, and congratulate him on his appointment as the next President of BCHP. His tireless efforts and commitment have hugely impacted BHCP and our patients in a positive manner,” says Gerard Villucci, CEO. “We know that as President, he will help lead BCHP to new heights and enable our practice to provide our patients with the highest quality treatments and care. Dr. Dozor’s extensive leadership experience will allow BCHP to continue to respond to the ever changing demands of the pediatric community.”

Dr. Dozor states, “I am humbled to take on this new role. My goals as a physician align with my goals as president. I am so proud of the growth of BCHP, and its long-standing commitment to superb patient care, medical research, training future generations of physicians, and advocating for the current and future health and well-being of children and families.”

Under Dr. Dozor’s leadership, the future is bright as he continues to make strides for BCHP and their patients. BCHP enthusiastically welcomes Dr. Dozor as their new president.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.